REVIEW ARTICLE
Vitamin D, Inflammation and Osteoporosis in Rheumatoid Arthritis
Pier Paolo Sainaghi1, 2, *, Antonello Gibbin3
Article Information
Identifiers and Pagination:
Year: 2018Volume: 12
Issue: Suppl-1, M9
First Page: 300
Last Page: 312
Publisher ID: TORJ-12-300
DOI: 10.2174/1874312901812010300
Article History:
Received Date: 22/4/2018Revision Received Date: 1/8/2018
Acceptance Date: 12/9/2018
Electronic publication date: 27/12/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Patients with Rheumatoid Arthritis (RA) commonly develop osteoporosis and fragility fractures. This fact cannot be explained only with the use of glucocorticoids, known to be detrimental for bone health. RA is characterized by a chronic inflammation caused by the continuous activation of innate and adaptive immunity with proinflammatory cytokines overproduction. This process is detrimental for several organs and physiological processes, including the impairment of bone remodeling. We will briefly review the pathogenesis of inflammation-related bone loss in RA, describing well-known and new molecular pathways and focusing on vitamin D and Parathyroid Hormone role.